4.7 Article

IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling

Journal

BLOOD
Volume 134, Issue 23, Pages 2092-2106

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019000396

Keywords

-

Categories

Funding

  1. National Health and Medical Research Council
  2. Ministry of Economy and Competitiveness
  3. European Regional Development Fund [SAF2014-56546-R, RTI2018-101105-B-I00]
  4. Deutsche Forschungsgemeinschaft (Bonn, Germany
  5. SFB877 project A1)
  6. Cluster of Excellence Inflammation at Interfaces

Ask authors/readers for more resources

Graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT) is characterized by interleukin-6 (IL-6) dysregulation. IL-6 can mediate effects via various pathways, including classical, trans, and cluster signaling. Given the recent availability of agents that differentially inhibit these discrete signaling cascades, understanding the source and signaling and cellular targets of this cytokine is paramount to inform the design of clinical studies. Here we demonstrate that IL-6 secretion from recipient dendritic cells (DCs) initiates the systemic dysregulation of this cytokine. Inhibition of DC-driven classical signaling after targeted IL-6 receptor (IL-6R) deletion in T cells eliminated pathogenic donor Th17/Th22 cell differentiation and resulted in long-term survival. After engraftment, donor DCs assume the same role, maintaining classical IL-6 signaling-dependent GVHD responses. Surprisingly, cluster signaling was not active after transplantation, whereas inhibition of trans signaling with soluble gp130Fc promoted severe, chronic cutaneous GVHD. The latter was a result of exaggerated polyfunctional Th22-cell expansion that was reversed by IL-22 deletion or IL-6R inhibition. Importantly, inhibition of IL-6 classical signaling did not impair the graft-versus-leukemia effect. Together, these data highlight IL-6 classical signaling and downstream Th17/Th22 differentiation as important therapeutic targets after alloSCT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Surgery

Patient-Reported Bowel, Urinary, and Sexual Outcomes After Laparoscopic-Assisted Resection or Open Resection for Rectal Cancer The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial (ALaCart)

Rebecca Mercieca-Bebber, Renee Eggins, Kilian Brown, Val J. Gebski, Kate Brewer, Lenna Lai, Lisa Bailey, Michael J. Solomon, John W. Lumley, Peter Hewett, Andrew D. Clouston, Kate Wilson, Wendy Hague, Julian Hayes, Stephen White, Matt Morgan, R. John Simes, Andrew R. L. Stevenson

Summary: This study aimed to compare the urinary, bowel, and sexual functioning of rectal cancer patients who underwent open or laparoscopic surgery. The results showed that patients who underwent open surgery had fewer symptoms in bowel and sexual functioning. However, it remains difficult to recommend one surgical approach over the other for rectal resection.

ANNALS OF SURGERY (2023)

Article Pathology

Placental Hepatic Nodule with Molecular Subtyping

Vanessa Young, Andrew Clouston, Sophie Corbett-Burns, Peter Russell

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2023)

Letter Hematology

Lithium attenuates graft-versus-host disease via effects on the intestinal stem cell niche

Motoko Koyama, Luke Samson, Kathleen S. Ensbey, Shuichiro Takahashi, Andrew D. Clouston, Paul J. Martin, Geoffrey R. Hill

BLOOD (2023)

Article Oncology

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston, Nigel J. Waterhouse, Amanda C. Stanley, Lucie Leveque-El Mouttie, Grace M. Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P. Brown, David Goldstein

Summary: This study evaluated the safety, efficacy, and pharmacodynamics of pixatimod and nivolumab in immunologically cold cancers. The combination therapy showed some antitumor activity in the MSS mCRC cohort, indicating the need for further investigation.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Neurosciences

The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130

Stephan A. Muller, Merav D. Shmueli, Xiao Feng, Johanna Tushaus, Neele Schumacher, Ryan Clark, Brad E. Smith, An Chi, Stefan Rose-John, Matthew E. Kennedy, Stefan F. Lichtenthaler

Summary: In this study, the researchers identified SEZ6 and gp130/IL6ST as physiological substrates of BACE1 in non-human-primate cerebrospinal fluid. They also found a reduction of gp130 in human CSF from a clinical trial with a BACE inhibitor and in plasma of BACE1-deficient mice. These findings provide insights into the relationship between BACE1 and gp130 in neuronal signaling and survival.

MOLECULAR NEURODEGENERATION (2023)

Article Immunology

Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia

Xiaoyu Zhang, Wenrui Yang, Donglin Yang, Jialin Wei, Ping Zhang, Sizhou Feng, Erlie Jiang, Li Zhang, Yi He, Fengkui Zhang, Mingzhe Han

Summary: Hepatitis-associated aplastic anemia is a rare type of acquired aplastic anemia characterized by bone marrow failure following hepatitis. The study analyzed the outcomes of severe HAAA patients treated with immunosuppressive therapy, matched-sibling donor hematopoietic stem cell transplantation, or haploidentical-donor HSCT as the first-line treatment. The findings showed that HSCT resulted in a higher and more sustained hematologic response compared to IST. Overall survival rates were similar among the treatment groups, but HSCT demonstrated a trend of better failure-free survival rates, particularly in young patients.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model

Agatha Schwarz, Rebecca Philippsen, Serena G. Piticchio, Jan N. Hartmann, Robert Haesler, Stefan Rose-John, Thomas Schwarz

Summary: The organ-specific microbiome, particularly the skin microbiome, plays a crucial role in tissue homeostasis by regulating the inflammatory response. Short chain fatty acids (SCFA) induce regulatory T cells (Treg) in the skin and their signal is mediated by the receptor HCA2. Knock-out of HCA2 results in stronger inflammation and a switch of Treg from a suppressive to a proinflammatory type, indicating that the skin microbiome dictates the outcome of the inflammatory reaction.

FRONTIERS IN IMMUNOLOGY (2023)

Letter Biophysics

Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia

Philip Wong, David C. Whiteman, Catherine M. Olsen, Yin Yuan, Jason Butler, Cameron Curley, Simon Durrant, Andrea Henden, James Morton, Elango Subramoniapillai, Caroline Stewart, Siok-Keen Tey, Glen A. Kennedy, Ashleigh P. Scott

BONE MARROW TRANSPLANTATION (2023)

Review Biophysics

PET assessment of acute gastrointestinal graft versus host disease

Ashleigh P. P. Scott, Andrea Henden, Glen A. A. Kennedy, Siok-Keen Tey

Summary: Acute gastrointestinal graft versus host disease (GI-GVHD) is a serious complication of allogeneic haematopoietic cell transplantation (HCT) with limited diagnostic methods. Innovative investigations using tissue-based biomarker assessment and molecular imaging by positron emission tomography (PET) have the potential to accurately guide GI-GVHD management. This article reviews the evidence regarding GI-GVHD diagnosis and explores the evolving role of PET in predicting or diagnosing GI-GVHD.

BONE MARROW TRANSPLANTATION (2023)

Article Immunology

Intestinal microbiota controls graft-versus-host disease independent of donor-host genetic disparity

Motoko Koyama, Daniel S. Hippe, Sujatha Srinivasan, Sean C. Proll, Oriana Miltiadous, Naisi Li, Ping Zhang, Kathleen S. Ensbey, Noah G. Hoffman, Christine R. Schmidt, Albert C. Yeh, Simone A. Minnie, Susan M. Strenk, Tina L. Fiedler, Namita Hattangady, Jacob Kowalsky, Willian M. Grady, Mariapia A. Degli-Esposti, Antiopi Varelias, Andrew D. Clouston, Marcel R. M. van den Brink, Neelendu Dey, Timothy W. Randolph, Kate A. Markey, David N. Fredricks, Geoffrey R. Hill

Summary: Acute graft-versus-host disease (aGVHD) is a major limitation of allogeneic stem cell transplantation (SCT), and severe intestinal manifestation is the leading cause of early mortality. Intestinal microbiota control MHC class II (MHC-II) expression by ileal intestinal epithelial cells (IECs), promoting GVHD. This study showed that genetically identical mice from different vendors had different intestinal microbiota and MHC-II expression levels, resulting in varying severity of GVHD.

IMMUNITY (2023)

Article Medicine, General & Internal

Relapsed nodular lymphocyte-predominant Hodgkin lymphoma presenting as severe paraneoplastic hepatitis: a case report

Anthony J. Deacon, Naeman N. Goetz, Nicholas Weber, Andrew Clouston, Enoka Gonsalkorala, Catherine Baskerville, Barbara Leggett

Summary: Hematological malignancies can cause liver dysfunction through various mechanisms, and paraneoplastic hepatitis is an extremely rare presentation. We present a case of paraneoplastic hepatitis caused by nodular lymphocyte-predominant Hodgkin lymphoma, which improved after treatment.

JOURNAL OF MEDICAL CASE REPORTS (2023)

Article Medicine, Research & Experimental

Human IL-10-producing Th1 cells exhibit a molecular signature distinct from Tr1 cells in malaria

Chelsea L. Edwards, Susanna S. Ng, Fabian de Labastida Rivera, Dillon Corvino, Jessica A. Engel, Marcela Montes de Oca, Luzia Bukali, Teija C. M. Frame, Patrick T. Bunn, Shashi Bhushan Chauhan, Siddharth Sankar Singh, Yulin Wang, Jinrui Na, Fiona H. Amante, Jessica R. Loughland, Megan S. F. Soon, Nicola Waddell, Pamela Mukhopadhay, Lambros T. Koufariotis, Rebecca L. Johnston, Jason S. Lee, Rachel Kuns, Ping Zhang, Michelle J. Boyle, Geoffrey R. Hill, James S. McCarthy, Rajiv Kumar, Christian R. Engwerda

Summary: Control of malaria requires Th1 cells with IL-10 to mitigate inflammation, but IL-10+Tr1 cells can also promote parasite persistence or impair immunity. Molecular and phenotypic signatures distinguish IL-10-Th1 cells from IL-10+Tr1 cells in malaria-infected individuals and mice, and a conserved Tr1 cell signature is found in patients with malaria, dengue, and graft-versus-host disease.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Review Immunology

Targeting IL-6 trans-signalling: past, present and future prospects

Stefan Rose-John, Brendan J. Jenkins, Christoph Garbers, Jens M. Moll, Juergen Scheller

Summary: This review discusses the discovery of the IL-6 trans-signalling pathway and the development of biologics that specifically inhibit this pathway. Targeting IL-6 trans-signalling can decrease disease-promoting activities of IL-6 without blocking its protective actions.

NATURE REVIEWS IMMUNOLOGY (2023)

Article Medicine, Research & Experimental

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

Simone A. Minnie, Olivia G. Waltner, Kathleen S. Ensbey, Stuart D. Olver, Alika D. Collinge, David P. Sester, Christine R. Schmidt, Samuel R. W. Legg, Shuichiro Takahashi, Nicole S. Nemychenkov, Tomoko Sekiguchi, Gregory Driessens, Ping Zhang, Motoko Koyama, Andrew Spencer, Leona A. Holmberg, Scott N. Furlan, Antiopi Varelias, Geoffrey R. Hill

Summary: Autologous stem cell transplantation (ASCT) with lenalidomide maintenance is a standard treatment for multiple myeloma. However, most patients eventually relapse, suggesting immune escape. This study shows that TIGIT is highly expressed on activated CD8+ T cells in mobilized peripheral blood stem cell grafts, and that targeting TIGIT in combination with lenalidomide can enhance antimyeloma efficacy and improve immune phenotypes.

JOURNAL OF CLINICAL INVESTIGATION (2023)

No Data Available